Physician profile
Fred Sesti
NPI 1174618516
$3,339.47
in general payments reported to CMS, 2019-2025
34 companies · $892 in 2025
The $892 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $528 · 2022: $476 · 2023: $792 · 2024: $652 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.91 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $889.69 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $279.90 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $263.34 | 2021-2025 | |
| Lilly USA, LLC | $216.45 | 2021-2025 | Verzenio, Jaypirca, Mounjaro |
| Amgen INC. | $179.26 | 2021-2025 | Repatha, Otezla, Repatha |
| Beigene USA, INC. | $171.76 | 2024 | Brukinsa |
| Pfizer INC. | $163.22 | 2021-2025 | |
| Glaxosmithkline, LLC. | $153.54 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.38 | 2021-2025 | Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $132.28 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $96.15 | 2021-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $95.19 | 2021-2024 | Imfinzi, Breztri |
| Daiichi Sankyo INC. | $53.37 | 2024-2025 | Injectafer |
| Astellas Pharma US INC | $48.89 | 2023-2025 | Vyloy, Veozah |
| Springworks Therapeutics, INC. | $43.19 | 2025 | Gomekli |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $35.49 | 2023-2024 | Cologuard Collection Kit |
| Array Biopharma INC | $35.28 | 2025 | Tukysa, Braftovi, Mektovi |
| Eisai INC. | $34.98 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $29.81 | 2025 | Opdivo |
| Beone Medicines USA, INC. | $24.14 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $23.18 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $22.77 | 2025 | Xpovio |
| Genmab U.S., INC. | $22.27 | 2024 | Epkinly |
| Kyowa Kirin, INC. | $22.10 | 2024 | Poteligeo |
| Sobi, INC | $18.18 | 2023 | |
| Nevro Corp. | $18.06 | 2023 | Senza |
| Puma Biotechnology, INC. | $16.86 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.30 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.01 | 2022 | |
| Exelixis INC. | $14.76 | 2025 | Cabometyx |
| Phathom Pharmaceuticals, INC. | $14.13 | 2024 | Voquezna |
| Genentech USA, INC. | $13.62 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.40 | 2024 | Quviviq |
| Amarin Pharma, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Sesti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.